The Significance of nab-Sirolimus and Future Directions in the Treatment of Perivascular Epithelioid Cell Tumor (PEComa): Richard F. Riedel, MD

Recently, the FDA granted approval to nanoparticle albumin-bound sirolimus (nab-sirolimus) for the treatment of patients with metastatic malignant perivascular epithelioid cell tumor (PEComa). Dr. Richard F. Riedel, Associate Professor of Medicine at Duke University, was one of the investigators of the AMPECT study, on which the approval was based. In this interview, Dr. Riedel speaks with Oncology Data Advisor about the significance of the approval of nab-sirolimus for the treatment of patients...

Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2022 Oncology Data Advisor. All rights reserved.